All In Biotech

NDA 050794 · Bristol-Myers

Vidaza

Azacitidine · Intravenous, Subcutaneous · Nucleoside Metabolic Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

May 19, 2004

Approved uses

4

Original approval plus efficacy supplements

Registered trials

1,227

154 Phase 3, 243 recruiting

FAERS reports

29,331

28,307 serious, 10,819 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 29, 2024.

VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of: • Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1.1 ) • Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML). ( 1.2 ) 1.1 Myelodysplastic Syndromes (MDS) VIDAZA ® is indicated for treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). 1.2 Juvenile Myelomonocytic Leukemia (JMML) VIDAZA is indicated for the treatment of pediatric patients aged one month and older with newly diagnosed JMML.

Mechanism: VIDAZA is a pyrimidine nucleoside analog of cytidine. VIDAZA is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including cancer cells that are no longer...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 20, 2022 Supplement 34 · Efficacy · priority review OrphanLabelLetter
  • Aug 20, 2008 Supplement 11 · Efficacy · priority review LabelLetter
  • Jan 26, 2007 Supplement 5 · Efficacy Label
  • May 19, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
  • VIDAZA · AZACITIDINE 100MG/VIAL · POWDER, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Azacitidine" as an intervention, any sponsor and status, largest first.

All 1,227 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3,321
  • febrile neutropenia3,027
  • acute myeloid leukaemia2,211
  • pneumonia2,017
  • neutropenia1,996
  • off label use1,992
  • myelosuppression1,806
  • pyrexia1,687
  • thrombocytopenia1,617
  • anaemia1,438
  • platelet count decreased1,279
  • sepsis1,266

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200555
200644
200743
200893
2009378
2010597
2011818
20121,084
2013921
20141,106
20151,042
2016876
20171,173
20181,371
20191,731
20201,790
20212,496
20223,148
20232,842
20242,725
20252,975
20262,005

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 16, 2026

    Vidaza, Injection, 100 mg (NDC 59572-102-01).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 431 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.